3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
13
Carcinoma, Squamous Cell
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
Sorafenib
79
pembrolizumab
37
Bevacizumab
36
Nivolumab
33
lenvatinib
30
atezolizumab
24
durvalumab
17
Oxaliplatin
12
Ipilimumab
12
regorafenib
9
Capecitabine
9
tremelimumab
8
Injections
8
Doxorubicin
8
tislelizumab
7
sintilimab
7
Fluorouracil
7
cabozantinib
6
budigalimab
6
brivanib
6
Ramucirumab
6
toripalimab
5
Gemcitabine
5
Everolimus
5
Cyclophosphamide
5
ADI PEG20
5
fludarabine
4
Sunitinib
4
Leucovorin
4
E-7386
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Hepatocellular
×
talimogene laherparepvec
×
Clear all
NCT02509507
2024-08-06
MASTERKEY-318
Amgen
Phase 1/2
Completed
127 enrolled
37 charts